BOB体育

Skip to main content
(352) 733-0111

Sacituzumab Govitecan Versus Treatment of Physician's Choice in Endometrial Cancer (ASCENT-GYN-01)

  • Status
    Accepting Candidates
  • Age
    18 Years - N/A
  • Sexes
    Female
  • Healthy Volunteers
    No
I'm interested
Share this study

Objective

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC).

The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).

Details

Full study title A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
Protocol number OCR45934
ClinicalTrials.gov ID NCT06486441
Phase Phase 3

Eligibility

Key Inclusion Criteria:

  • Documented evidence of recurrent/persistent endometrial cancer (endometrial carcinoma or carcinosarcoma).

  • Up to 3 prior lines of systemic therapy for endometrial cancer, including systemic platinum-based chemotherapy and anti-PD-1/PD-L1 therapy, either in combination or separately.

  • Eligible for treatment with either doxorubicin or paclitaxel as determined by the investigator.

  • Radiologically evaluable disease (either measurable or nonmeasurable) by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1.

  • Eastern Cooperative Oncology Group performance status score of 0 or 1.

  • Adequate organ function

Key Exclusion Criteria:

  • Uterine leiomyosarcoma and endometrial stromal sarcomas are excluded.

  • Participants who are candidates for curative-intent therapy at the time of study enrollment.

  • Participants eligible for rechallenge with platinum-based chemotherapy as determined by the investigator.

  • Received any prior treatment with a Trop-2-directed antibody-drug conjugate (ADC).

  • Have an active second malignancy.

  • Have an active serious infection requiring systemic antimicrobial therapy.

  • Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months prior to randomization.

  • Have a positive serum pregnancy test or are breastfeeding for participants who are assigned female at birth.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Lead researcher

  • Merry J Markham, MD, FACP FASCO
    Cancer Specialist (Oncologist), Hematologist (Blood Disease Specialist), Hematology and Oncology Specialist

Participate in a study

Here are some general steps to consider when participating in a research study:

  1. Step
    1

    Contact the research team

    Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.

    Primary contact

  2. Step
    2

    Get screened to confirm eligibility

    You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.

  3. Step
    3

    Provide your consent to participate

    If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.

  4. Step
    4

    Participate

    If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.